




Contents lists available at ScienceDirect

Brain Behavior and Immunity

journal homepage: www.elsevier.com/locate/ybrbi

Full-length Article



Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice

Adriano Lama^a, Claudio Pirozzi^a, Ilenia Severi^b, Maria Grazia Morgese^c, Martina Senzacqua^b, Chiara Annunziata^a, Federica Comella^a, Filomena Del Piano^d, Stefania Schiavone^c, Stefania Petrosino^e, Maria Pina Mollica^f, Sabrina Diano^{g,h,i,j}, Luigia Trabace^c, Antonio Calignano^a, Antonio Giordano^b, Giuseppina Mattace Raso^{a,1,*}, Rosaria Meli^{a,1}

^a Department of Pharmacy, School of Medicine, University of Naples Federico II, Via Domenico Montesano, 49 - 80131 Naples, Italy

^b Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Tronto, 10, A - 60020 Ancona, Italy

^c Department of Clinical and Experimental Medicine, University of Foggia, Via Napoli, 20 - 71122 Foggia, Italy

^d Department of Veterinary Medicine and Animal Production, University of Naples Federico II, Via Delpino 1, 80137 Naples, Italy

^e Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Napoli, Italy

^f Department of Biology, University of Naples Federico II, Complesso Universitario di Monte Sant'Angelo, Cupa Nuova Cinthia 21 - Edificio 7, 80126 Naples, Italy

^g Program in Cell Signaling and Neurobiology of Metabolism, Yale University School of Medicine, New Haven, CT 06520, USA

^h Department of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520, USA

ⁱ Department of Neuroscience, Yale University School of Medicine, New Haven, CT 06520, USA

^j Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520, USA

ARTICLE INFO

Keywords:

High-fat diet
Metabolic impairment
Inflammation
Mood disorders
Astrogliosis
Microgliosis
Mastocytosis
Blood–brain barrier permeability
N-acylethanolamines
Peroxisome proliferator-activated receptor- α

ABSTRACT

High-fat diet (HFD) consumption leads to obesity and a chronic state of low-grade inflammation, named meta-inflammation. Notably, meta-inflammation contributes to neuroinflammation due to the increased levels of circulating free fatty acids and cytokines. It indicates a strict interplay between peripheral and central counterparts in the pathogenic mechanisms of obesity-related mood disorders. In this context, the impairment of internal hypothalamic circuitry runs in tandem with the alteration of other brain areas associated with emotional processing (i.e., hippocampus and amygdala). Palmitoylethanolamide (PEA), an endogenous lipid mediator belonging to the N-acylethanolamines family, has been extensively studied for its pleiotropic effects both at central and peripheral level.

Our study aimed to elucidate PEA capability in limiting obesity-induced anxiety-like behavior and neuroinflammation-related features in an experimental model of HFD-fed obese mice.

PEA treatment promoted an improvement in anxiety-like behavior of obese mice and the systemic inflammation, reducing serum pro-inflammatory mediators (i.e., TNF- α , IL-1 β , MCP-1, LPS). In the amygdala, PEA increased dopamine turnover, as well as GABA levels. PEA also counteracted the overactivation of HPA axis, reducing the expression of hypothalamic corticotropin-releasing hormone and its type 1 receptor. Moreover, PEA attenuated the immunoreactivity of Iba-1 and GFAP and reduced pro-inflammatory pathways and cytokine production in both the hypothalamus and hippocampus. This finding, together with the reduced transcription of mast cell markers (chymase 1 and tryptase β 2) in the hippocampus, indicated the weakening of immune cell activation underlying the neuroprotective effect of PEA. Obesity-driven neuroinflammation was also associated with the disruption of blood–brain barrier (BBB) in the hippocampus. PEA limited the albumin extravasation and

Abbreviations: 5-HIAA, 5-hydroxy-indol acetic acid; ACTH, adrenocorticotropic hormone; AMY, amygdala; BBB, blood-brain barrier; Cldn5, claudin 5; CRH, corticotropin-releasing hormone; DA, dopamine; DG, dentate gyrus; DOPAC, 3,4-dihydroxyphenylacetic acid; FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; GABA, γ -aminobutyric acid; GFAP, glial fibrillary acidic protein; GLU, glutamic acid; HFD, high-fat diet; HPA, hypothalamic-pituitary-adrenal; HVA, homovanillic acid; IL, interleukin; LPS, lipopolysaccharide; MCP, monocyte chemoattractant protein; MyD, myeloid differentiation primary response gene; NA, noradrenaline; NLRP3, NLR family pyrin domain containing 3; Occludin, occludin; OCR, oxygen consumption rate; PEA, palmitoylethanolamide; PPAR, peroxisome proliferator-activated receptor; STD, control group; Tjp1, tight junction protein 1; TLR, toll-like receptor; TNF, tumor necrosis factor.

* Corresponding author.

E-mail address: mattace@unina.it (G. Mattace Raso).

¹ These authors contributed equally to the study as senior authors.

<https://doi.org/10.1016/j.bbi.2022.02.008>

Received 29 June 2021; Received in revised form 1 February 2022; Accepted 4 February 2022

Available online 14 February 2022

0889-1591/© 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

restored tight junction transcription modified by HFD. To gain mechanistic insight, we designed an *in vitro* model of metabolic injury using human neuroblastoma SH-SY5Y cells insulted by a mix of glucosamine and glucose. Here, PEA directly counteracted inflammation and mitochondrial dysfunction in a PPAR- α -dependent manner since the pharmacological blockade of the receptor reverted its effects.

Our results strengthen the therapeutic potential of PEA in obesity-related neuropsychiatric comorbidities, controlling neuroinflammation, BBB disruption, and neurotransmitter imbalance involved in behavioral dysfunctions.

1. Introduction

Fat overnutrition leads to metabolic dysfunction at the peripheral level due to multiple and parallel mechanisms involving different compartments and converging to a state of low-grade inflammation, known as meta-inflammation (Li et al., 2018). Furthermore, high-fat diet (HFD) intake leads to the loss of gut barrier integrity, causing the transfer of macromolecules, such as microbial- or pathogen-associated molecular patterns (i.e., lipopolysaccharide, LPS) into the systemic circulation.

The inflammatory response to overnutrition at the central level, above all in the hypothalamus, develops more rapidly than peripheral tissues, damaging the neurocircuits related to fasting and feeding before overt obesity (Waiss et al., 2015). Hypothalamic inflammation is sustained by the peripheral inflammatory and immune signals, activating microglial cells and astrocytes (Valdearcos et al., 2017). In this scenario, mast cells act as early players of neuroinflammation through the production and the release of neurotoxic factors that impair blood–brain barrier (BBB) integrity, already undermined by systemic inflammation (Skaper et al., 2017; Wang et al., 2020). Following long-term HFD feeding, inflammation may affect extra-hypothalamic brain areas involved in mood regulation and anxiety (i.e., prefrontal cortex, amygdala or AMY, hippocampus) (Guillemot-Legrès and Muccioli, 2017). The bidirectional mechanisms linking obesity and anxiety shared pathophysiological processes converging in metabolic dysfunction and neuroinflammation. Obesity and insulin resistance, secondary to the excessive consumption of HFD, are events often associated with neuropsychiatric illnesses (Baker et al., 2017; Milaneschi et al., 2019; Tsan et al., 2021).

During the last years, many studies have focused on both metabolic and neuroprotective effects of palmitoylethanolamide (PEA), an endogenous lipid mediator whose activity is mainly mediated by peroxisome proliferator-activated receptor (PPAR)- α (Locci and Pinna, 2019; Mattace Raso et al., 2014a). PEA improves metabolic alterations in several murine models of obesity: it restores hypothalamic leptin signaling, modulates orexigenic and anorexigenic neurocircuitries (Mattace Raso et al., 2014b), and counteracts the metabolic dysfunction caused by lipid overload in an AMP-activated protein kinase-dependent manner (Annunziata et al., 2020). Recently, we have highlighted that PEA limits the depressive- and anhedonic-like behavior in obese mice, stimulating synaptic plasticity and neurogenesis (Lama et al., 2021).

Here, we investigated the effects of PEA on HFD-induced anxiety-like behavior in mice in relation to its capability in limiting immune cell activation and neuroinflammation in the hypothalamus and hippocampus. We also performed *in vitro* experiments on human SH-SY5Y cells insulted by a metabolic challenge to provide evidence for the involvement of PPAR- α . Here, we determined PEA modulation of inflammation and mitochondrial bioenergetics.

2. Materials and methods

2.1. Animals and treatments

Male C57Bl/6J mice (Charles River, Wilmington, MA, USA) at six weeks of age housed in stainless steel cages in a room kept at 22 ± 1 °C with a 12:12 h light-dark cycle. They were randomly divided into three

groups (11 animals for each group) as follows: control group (STD) receiving chow diet (Mucedola Srl, Milan, Italy) and vehicle; HFD (Research Diets Inc, NJ, USA) group receiving vehicle; HFD group treated with PEA (HFD + PEA, 30 mg/kg daily per os). The treatments started 12 weeks after HFD feeding and lasted seven weeks along with HFD (Fig. 1). STD diet had 17% fat without sucrose, while HFD had 45% energy derived from fat and 7% sucrose. We used PEA in the ultra-micronized formulation provided by Epitech Group Research Labs (Padua, Italy), dissolved in carboxymethyl cellulose (1.5%). Preliminary experiments showed no significant modification of body weight, fat mass, or energy intake in PEA-treated STD animals compared to the STD group (Figure S1). Furthermore, central variables depending on obesity (i.e., anxiety-like behavior and neuroinflammation) were not induced in STD mice. Therefore, the STD diet-fed group treated with PEA was not included. Animals were sacrificed by an i.p. injection of a mixture of ketamine/xylazine followed by cervical dislocation. All animal experiments were conducted under license number 982/2017-PR released by the Italian Ministry of Health. All procedures involving the animals were carried out following the Institutional Guidelines and complied with the Italian D.L. no.116 of January 27, 1992 of Ministero della Salute and associated guidelines in the European Communities Council (86/609/ECC and 2010/63/UE).

2.2. Open field test

The open field test is one of the most used to obtain general information about locomotor activity and emotionality of animals (Seibenhener and Wooten, 2015). Indeed, the experimenter can evaluate anxiety-like behavior by evaluating mice's propensity to avoid open areas perceived as dangerous, namely thigmotaxis. Briefly, mice were placed in an open-field arena and allowed to explore for 30 min. After each trial, the arena floor was cleaned with 70% ethanol to delete odor cues for the next subject. The movements of mice were recorded by the infrared video camera and analyzed by Any-maze-tracking software (Stoelting Co., Wood Dale, IL, U.S.A.). The evaluated parameters from the open field test were: 1) the percentage of covered distance in the central area [(distance travelled in the centre/total travelled distance) \times 100]; 2) the number of entries in the central area; 3) total travelled distance (in m).

2.3. Neurochemical quantification (monoamine analyses)

Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-HT, and 5 hydroxy-indol acetic acid (5-HIAA) levels were measured in the AMY of all mice by HPLC coupled with an electrochemical detector (Ultimate ECD, Dionex Scientific, Milan, Italy) as already reported (Lama et al., 2021). The separation was performed by a LC18 reverse phase column (Kinetex, 150 mm \times 3.0 mm, ODS 5 μ m; Phenomenex, Castel Maggiore- Bologna, Italy). The detection was accomplished by a thin-layer amperometric cell (Dionex, Thermo-Scientific, Milan, Italy) with a 5-mm diameter glassy carbon electrode at a working potential of 400 mV vs. Pd. The mobile phase consisted of an aqueous buffer containing 75 mM NaH₂PO₄, 1.7 mM octane sulfonic acid, 0.3 mM EDTA, acetonitrile 10%, buffered at pH 3.0. The flow rate was maintained by an isocratic pump (Shimadzu LC-10 AD, Kyoto, Japan) at 0.7 ml/min. Data were acquired and integrated using

Chromleon software (version 6.80, Dionex, Thermo Scientific, San Donato Milanese, Italy). Glutamic acid (GLU) and γ -aminobutyric acid (GABA) were quantified by using HPLC coupled with fluorimetric detection (emission length, 4.60 nm; excitation length, 3.40 nm). Chromatographic detection was accomplished by ODS-3 column (150 \times 4.6 mm, 3 μ m; INERTSIL) after derivatization with ophthalaldehyde/mercaptpropionic acid. The mobile phase gradient was 50 mM sodium acetate buffer, pH 6.95, with methanol increasing linearly from 2 to 30% (v/v) over 40 min. The flow rate was maintained by a pump (JASCO, Tokyo, Japan) at 0.5 ml/min. Results were analyzed by Borwin software (version 1.50; Jasco), and substrate concentration was expressed as μ M.

2.4. Serum parameters analysis

Serum samples, collected at the end of the experimental period, were assayed for LPS, monocyte chemoattractant protein (MCP)-1, tumor necrosis factor (TNF)- α , interleukin (IL)-1 β , corticotropin-releasing hormone (CRH), and adrenocorticotrophic hormone (ACTH).

LPS was measured using the Limulus ameobocyte lysate (LAL QCL-1000; Lonza Group Ltd., Basel, Switzerland) technique. IL-1 β (Thermo Fisher Scientific, Rockford, IL), TNF- α , and MCP-1 (Biovendor R&D, Brno, Czech Republic) were measured using commercially available ELISA kits. Corticosterone (Cat#ab108821) and ACTH (Cat#ab263880) were quantified using commercially available ELISA kits (Abcam, Cambridge, UK) according to the manufacturer's instructions. All samples and standards were analyzed in duplicate to avoid intra-assay variations.

2.5. Peroxidase immunohistochemistry and morphometric analysis

Mice from each experimental group were anesthetized with the intraperitoneal ketamine/xylazine solution and transcardially perfused with a saline solution (0,9% NaCl in dH₂O) containing heparin (10 mg/l) (Cat#2106; Sigma-Aldrich, Milan, Italy) followed by fixative (4% paraformaldehyde, 15% picric acid, 0,1% glutaraldehyde in PBS). Brains were carefully removed from the skull, post-fixed in the same fixative solution for 24 h at 4 °C and washed in PBS. Free-floating 40- μ m-thick coronal brain sections were cut with a Leica VT1200S vibratome (Leica Microsystems, Vienna, Austria) and kept in PBS (pH 7.4) at 4 °C until use in immunohistochemical experiments.

Free-floating brain sections were reacted with 1% NaOH and 1% H₂O₂ (20 min), 0.3% glycine (10 min), and 0.03% sodium dodecyl sulphate (10 min). After rinsing in PBS, they were blocked with 3% normal serum (in 0,2% Triton X-100; 60 min) and incubated with mouse monoclonal IgG anti-Iba1 (Wako, Shanghai, China, # 019–19741; dilution at 1:1500) or mouse monoclonal IgG anti-gial fibrillary acidic protein (GFAP) (Merck, St. Louis, Missouri, USA; #G3893; dilution at

1:1000) in PBS, overnight at 4°C. The next day, after a thorough rinse in PBS, sections were incubated in 1:200 v/v biotinylated secondary antibody solution (in PBS; 30 min), rinsed in PBS, and incubated in avidin–biotin peroxidase complex (ABC Elite PK6100, Vector Laboratories, Burlingame, CA, USA), washed several times in PBS, and finally incubated in 3,3' diaminobenzidine tetrahydrochloride (0.05% in 0.05 M Tris with 0.03% H₂O₂; 5 min). After immunohistochemical staining, sections were mounted on slides, air-dried, dehydrated in ethanol, cleared with xylene, and covered with Eukitt. Staining was never detected when the primary antibody was omitted.

Morphometric analyses were performed on five mice for each experimental group. From each mouse, three non-adjacent and corresponding brain coronal sections containing the tuberal hypothalamus and the hippocampus (from bregma – 1.46 mm to bregma – 1.94 mm according to Paxinos and Franklin, 2019) were immunostained for Iba1 and GFAP. Adjacent sections were used to identify the exact location of the arcuate nucleus of the hypothalamus, the dentate gyrus (DG), and the stratum radiatum of the CA1 of the hippocampus by Nissl staining. The number of Iba1-positive microglial cells was manually counted at 10x magnification. In contrast, GFAP immunostaining was scored in 40x photographs by assessing the percentage of GFAP staining in astrocyte somata and processes with the ImageJ software using threshold values to standardize intensity (NIH, Bethesda, MD, USA). GFAP positive processes of astrocytes are often entangled with each other and for this reason a more affordable method of morphometric evaluation is the assessment of the area of GFAP specific staining, as widely reported (Berkseth et al., 2014; Douglass et al., 2017). Measures were taken in each hemisphere's left, and right values were added up for each slice and averaged in each mouse. Measurements were performed by an experimenter who was blinded to the identity of the treatment group.

2.6. Immunofluorescence, confocal microscopy, and morphometric analysis

For double fluorescent immunohistochemistry, free-floating brain sections were processed as above up to incubation with the primary antibody. They were then incubated overnight in a mixture of two primary antibodies: goat polyclonal IgG anti-albumin (Novus Biologicals, Centennial, CO, USA, Cat # NB600-41532; dilution at 1:2000 v/v) and mouse monoclonal IgG anti-NeuN (Millipore, Burlington, MA, USA, Cat # MAB377; dilution at 1:100 v/v). The next day, sections were washed twice with PBS and incubated in a cocktail of fluorophore-linked secondary antibodies at a dilution of 1:400 in PBS for one hour at room temperature. The secondary antibodies were Alexa Fluor® 488 donkey anti-goat IgG and Alexa Fluor® 555 donkey anti-mouse IgG (both from Invitrogen, Carlsbad, CA, USA). Subsequently, sections were washed twice with PBS, counterstained with TO-PRO3-iodide, mounted on




Fig. 1. The experimental protocol. Mice of the experimental HFD groups received HFD for 12 weeks, while the STD group was fed with a standard chow diet. After 12 weeks on diet, the STD group received the vehicle, while HFD groups received either vehicle or ultra-micronized PEA (30 mg/kg daily p.o.) for seven weeks along with HFD.

standard glass slides, air-dried, and coverslipped using Vectashield mounting medium (Vector Laboratories). Sections were viewed under a motorized Leica DM6000 microscope at different magnifications. Fluorescence was detected with a Leica TCS-SL spectral confocal microscope equipped with an Argon and He/Ne mixed gas laser. Fluorophores were excited with the 488 nm, 543 nm, and 649 nm lines and imaged separately. Images (1024 × 1024 pixels) were obtained sequentially from two channels using a confocal pinhole of 1.1200 and stored as TIFF files. The brightness and contrast of the final images were adjusted using Photoshop 6 (Adobe Systems, Mountain View, CA, USA).

Morphometric analysis was performed on corresponding hippocampus-containing brain coronal sections processed in parallel. One section for each mouse and five mice for each experimental group was analyzed. The number of albumin-immunoreactive neuronal profiles are shown from both left and right DG and CA1 hippocampal subfield.

2.7. Cell culture and treatments

SH-SY5Y neuroblastoma cells (ATCC® number CCL-2266) were cultured in DMEM-F12 medium with 10% FBS, 100 IU/ml penicillin, and 100 mg/ml streptomycin at 37 °C in a humidified atmosphere with 5% CO₂. After 6-hour starvation in 2% FBS medium, cells were incubated for 24 h with a mix of 55 mM glucose (CARLO ERBA Reagents, Milan, Italy) and 2 mM glucosamine (Gluc2, Merck Life Science, Milan, Italy) to mimic the metabolic impairment induced by HFD in mice (Mi et al., 2017). One hour before Gluc2 challenge, cells were pretreated with PEA (10 μM) in the presence or not of PPAR-α antagonist, GW6471 (2 μM, Tocris Bioscience, Bristol, UK), added 30 min before PEA. After treatments, cells were collected, and mRNA extracts were obtained for additional analysis. The results were obtained from three different experiments.

2.8. Seahorse assay

SH-SY5Y cells underwent XF Cell Mito Stress Test kit using Seahorse Bioscience XFe24 Analyzer (Agilent Technologies, Santa Clara, CA, USA) to reveal critical parameters of cellular metabolism, as previously described (Pirozzi et al., 2020). Briefly, SH-SY5Y cells were seeded in mini plates at 80,000 cells/well in growth medium overnight, stimulated with Gluc2, in the presence or not of PEA and/or GW6471. Before starting XF assay, the medium was replaced with Seahorse XF DMEM assay medium (pH 7.4), and the cells were equilibrated at 37 °C in a CO₂-free incubator for 1 h. Mito Stress Assay evaluates the oxygen consumption rate (OCR, pmol/min) under baseline or stressed conditions. The proton leak and ATP-linked respiration were determined after the injection of 1 μM oligomycin (as an inhibitor of the F₀/F₁ ATPase). Afterward, the mitochondrial electron transport chain was maximally stimulated by adding the uncoupler carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 0.5 μM). The extra-mitochondrial respiration was determined after injecting mixed rotenone (1 μM)/antimycin A (0.5 μM), complexes I and III inhibitors. All parameters were calculated through Seahorse Wave Desktop Software (Agilent Technologies, Santa Clara, CA, USA). OCR was normalized to the protein content (μg/ml) of each well for all measurements by Bradford assay. The results were obtained from three different experiments.

2.9. Quantification of gene expression using Real-Time PCR

Total RNA, isolated from the mouse hypothalamus and hippocampus, and SH-SY5Y cells, was extracted using TRIzol Reagent (Bio-Rad Laboratories, Hercules, CA, USA) and assayed as previously described (Lama et al., 2019; Lama et al., 2021). Each sample contained 500 ng cDNA in 2X QuantiTect SYBR Green PCR Master Mix and primers pairs to amplify mouse chymase 1 (*Cma1*), tryptase β2 (*Tpsb2*), NF-KB

(*Nfkb1*), IL-1β (*Il1b*), CRH (*Crh*), CRH receptor 1 (*Crhr1*), TNF-α (*Tnf*), myeloid differentiation primary response gene 88 (*Myd88*), toll-like receptor (TLR)2 (*Tlr2*), tight junction protein 1 (*Tjp1*), occludin (*Ocln*), and claudin 5 (*Cldn5*) (Qiagen, Hilden, Germany), human NLR family pyrin domain containing 3 (NLRP3), TLR4 (Qiagen, Hilden, Germany), and TNF-α (5′-GGC AGT CAG ATC ATC TTC TCG AA -3′; 5′-TGA AGA GGA CCT GGG AGT AGA TG -3′) (IDT Technologies, Coralville, IA, USA) in a final volume of 50 μl. The relative amount of each studied mRNA was normalized to actin as a housekeeping gene, and data were analyzed according to the 2^{-ΔΔCT} method.

2.10. Western blotting

Hippocampal lysates were subjected to SDS-PAGE. The blot was performed by transferring proteins from a slab gel to a nitrocellulose membrane at 240 mA for 60 min at room temperature. The filter was then blocked with 1X PBS (pH 7.4) and 5% non-fat dried milk for 60 min at room temperature and probed with rabbit polyclonal antibody against anti-TLR4 (1:1000; Cat#Sc-3002; Santa Cruz Biotechnology, Dallas, TX, USA). Western blot for anti-β-actin (1:5000; Cat#A5441; Sigma-Aldrich, Milan, Italy) was performed to ensure equal sample loading. The detection of the filter was performed by ChemiDoc Imaging System (Bio-Rad Laboratories, Hercules, CA, USA).

2.11. Data and statistical analysis

Data are presented as mean ± SEM. All experiments were analyzed using analysis of variance (ANOVA) for multiple comparisons followed by Bonferroni's post hoc test, using GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA). Normality was tested using the Shapiro-Wilk test. Bonferroni's post hoc test was run when F was significant. Differences among groups were considered significant at values of p < 0.05.

3. Results

3.1. PEA improves anxiety-like behavior induced by HFD and modulates DA turnover and GABA level in AMY.

During open field test, obese mice showed a significant increase of thigmotaxis and latency to enter the central zone of the open field, as demonstrated by the reduced total distance travelled in the centre (Fig. 2A, F (2, 30) = 0.2204; STD: 8.523 ± 0.668; HFD: 4.071 ± 0.529; p < 0.0001) and the number of entries into this area (Fig. 2B, F (2, 30) = 0.4252; STD: 78.36 ± 6.742; HFD: 41.36 ± 5.501; p = 0.0002). This tendency was counteracted by PEA treatment, that stimulated mice to explore the whole arena, increasing both the total distance (HFD + PEA: 6.936 ± 0.565; p = 0.2008 vs STD; p = 0.0053 vs HFD) and the number of entries in the centre (HFD + PEA: 62.18 ± 4.647; p = 0.1608 vs STD; p = 0.0446 vs HFD). In open field test, no significant change in mice movement was shown between PEA-treated and untreated obese mice in total distance travelled (Fig. 2C, F (2, 30) = 1.490; STD: 53.71 ± 3.193; HFD: 37.85 ± 2.781, p = 0.0008 vs STD; HFD + PEA: 46.67 ± 2.029; p = 0.2278 vs STD; p = 0.0859 vs HFD). Moreover, all mice were subjected to rotarod test, revealing no difference among groups in motor coordination (data not shown).

Considering the pivotal role of AMY in the response to stressors, we evaluated the levels of many neurotransmitters in this area obtained from all animal groups. To this purpose, we evaluated the levels of DA, and its metabolites (DOPAC and HVA), noradrenaline (NA), and 5-HT, together with its metabolite 5-HIAA. After 7 weeks of PEA treatment, mice showed a reduction of DA levels (Fig. 2D, F (2, 15) = 0.7377; STD: 251.2 ± 26.42; HFD: 316.9 ± 22.00, p = 0.1442 vs STD; HFD + PEA: 229.6 ± 14.68, p > 0.9999 vs STD; p = 0.0357 vs HFD). Although the levels of DOPAC (Fig. 2E, F (2, 15) = 4.711; STD: 1230 ± 462; HFD: 494.7 ± 124.1, p = 0.2696 vs STD; HFD + PEA: 1458 ± 132.6; p > 0.9999 vs STD p = 0.0936 vs HFD) and HVA (Fig. 2F, F (2, 15) = 1.190;




Fig. 2. PEA limits the anxiety-like behavior of obese mice. (A) Total distance in the centre, (B) the number of entries into the centre, and (C) the total distance travelled by mice in the open field test ($n = 11$ per group). The levels of (D) DA, (E) DOPAC, (F) HVA, and (G) DA turnover, (H) NA, (I) 5-HT, (J) 5-HIAA, and (K) 5-HT turnover ($n = 6$ per group) in AMY of all mice. The levels of (L) GABA and (M) GLU in AMY of all experimental groups ($n = 5$ per group). All data are shown as mean \pm S.E.M. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$.

STD: 538.6 ± 113.3 ; HFD: 291.9 ± 50.65 , $p = 0.1061$ vs STD; HFD + PEA: 567.2 ± 40.89 ; $p > 0.9999$ vs STD $p = 0.0627$ vs HFD) did not significantly differ among groups, PEA increased the turnover of DA (Fig. 2G, $F(2, 15) = 2.790$, STD: 7.664 ± 1.944 ; HFD: 4.293 ± 1.249 , $p = 0.3136$ vs STD; HFD + PEA: 10.28 ± 0.608 ; $p = 0.6004$ vs STD $p = 0.0234$ vs HFD). Furthermore, PEA slightly decreased the levels of NA (Fig. 2H, $F(2, 15) = 1.268$; STD: 194.4 ± 14.13 ; HFD: 299.5 ± 29.34 , $p = 0.0051$ vs STD; HFD + PEA: 254.9 ± 8.969 ; $p = 0.1337$ vs STD $p = 0.3809$ vs HFD) and 5-HT (Fig. 2I, $F(2, 15) = 2.107$; STD: 85.29 ± 22.20 ; HFD: 171.9 ± 7.218 , $p = 0.0197$ vs STD; HFD + PEA: 144.0 ± 24.21 ; $p = 0.1482$ vs STD $p = 0.9785$ vs HFD), strongly altered by HFD. Although the levels of 5-HIAA resulted high in obese mice and reduced by PEA (Fig. 2J, $F(2, 15) = 2.636$; STD: 584.7 ± 87.15 ; HFD: 2233 ± 426.1 , $p = 0.0010$ vs STD; HFD + PEA: 950.7 ± 10.45 ; $p = 0.9576$ vs STD $p = 0.0077$ vs HFD), 5-HT turnover did not differ among group (Fig. 2K, $F(2, 15) = 2.157$; STD: 9.148 ± 2.152 ; HFD: 12.12 ± 0.783 , $p = 0.7883$ vs STD; HFD + PEA: 8.186 ± 2.135 ; $p > 0.9999$ vs STD $p = 0.4334$ vs HFD). In addition, aminoacidic neurotransmitter levels, such as GLU and GABA, were also evaluated. HFD induced a significant decrease in GABA content in the AMY of obese mice, while PEA administration restored GABA levels (Fig. 2L, $F(2, 12) = 0.6647$; STD: 95.14 ± 11.95 ; HFD: 21.85 ± 6.107 , $p = 0.0107$ vs STD; HFD + PEA: 109.8 ± 21.58 ; $p = 0.7643$ vs STD $p = 0.0031$ vs HFD). Conversely, GLU levels did not differ among all groups (Fig. 2M, $F(2, 12) = 0.0490$; STD: 69.86 ± 8.765 ; HFD: 52.93 ± 7.287 , $p = 0.2861$ vs STD; HFD + PEA: 42.63 ± 6.299 ; $p = 0.0603$ vs STD $p = 0.6096$ vs HFD).

3.2. PEA counteracts the systemic inflammation in obese mice.

Because of the HFD-induced gut leakiness (Araujo et al., 2017), we also evaluated the anti-inflammatory and immunomodulatory activity of PEA in serum samples of all experimental groups. In particular, we showed that PEA limited the endotoxemia induced by HFD, reducing the serum levels of LPS (Fig. 3A, $F(2, 15) = 20.49$; STD: 0.7652 ± 0.033 ; HFD: 1.645 ± 0.096 , $p < 0.0001$ vs STD; HFD + PEA: 1.169 ± 0.022 ; $p = 0.0008$ vs STD; $p = 0.0001$ vs HFD) and the chemoattractant MCP-1 (Fig. 3B, $F(2, 15) = 1.301$; STD: 27.67 ± 0.882 ; HFD: 79 ± 1.732 , $p < 0.0001$ vs STD; HFD + PEA: 47.67 ± 2.525 ; $p < 0.0001$ vs STD; $p < 0.0001$ vs HFD). Furthermore, PEA confirmed its remarkable anti-inflammatory properties, as demonstrated by the reduction of serum TNF- α (Fig. 3C, $F(2, 15) = 0.9185$; STD: 0.9233 ± 0.049 ; HFD: 3.867 ± 0.095 , $p < 0.0001$ vs STD; HFD + PEA: 1.473 ± 0.126 ; $p = 0.0030$ vs STD; $p < 0.0001$ vs HFD) and IL-1 β (Fig. 3D, $F(2, 15) = 3.783$; STD: 1.820 ± 0.032 ; HFD: 6.335 ± 0.218 , $p < 0.0001$ vs STD; HFD + PEA: 3.681 ± 0.070 ; $p < 0.0001$ vs STD; $p < 0.0001$ vs HFD).

The serum levels of corticosterone (Fig. 3E, $F(2, 15) = 2.343$; STD: 1087 ± 43.55 ; HFD: 1042 ± 139.8 , $p > 0.9999$ vs STD; HFD + PEA: 1098 ± 101.3 ; $p > 0.9999$ vs STD; $p > 0.9999$ vs HFD) and ACTH (Fig. 3F, $F(2, 15) = 0.7741$; STD: 374 ± 26.44 ; HFD: 430.4 ± 40.71 , $p = 0.7836$ vs STD; HFD + PEA: 412.8 ± 33.89 ; $p > 0.9999$ vs STD; $p > 0.9999$ vs HFD) did not differ among the groups.

3.3. PEA attenuates HFD-induced hypothalamic injury of obese mice.

After 19 weeks of HFD intake, obese mice showed an increased transcription of NF-KB (Fig. 4A, $F(2, 12) = 0.695$; STD: 1.000 ± 0.060 ;




Fig. 3. PEA improves systemic parameters altered by HFD. Serum levels of (A) LPS, (B) MCP-1, (C) TNF- α , (D) IL-1 β , (E) corticosterone and (F) ACTH (n = 6 per group). All data are shown as mean \pm S.E.M. ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

HFD: 1.910 ± 0.174 , $p = 0.0022$ vs STD) and IL-1 β (Fig. 4B, F (2, 12) = 0.9217; STD: 1.000 ± 0.091 ; HFD: 3.548 ± 0.315 , $p < 0.0001$ vs STD) in hypothalamus, while PEA treatment limited these pro-inflammatory mediators (for NF-KB: HFD + PEA: 1.311 ± 0.166 ; $p = 0.4510$ vs STD; $p = 0.0357$ vs HFD; for IL-1 β : HFD + PEA: 1.957 ± 0.308 ; $p = 0.0689$ vs STD; $p = 0.0029$ vs HFD). Then, we also evaluated mRNA expression of CRH and its receptor CRHR1, whose central alteration suggests a dysregulation of hypothalamic–pituitary–adrenal (HPA) axis. PEA limited the increased transcription of CRH (Fig. 4C, F (2, 12) = 1.085; STD: 1.000 ± 0.104 ; HFD: 1.947 ± 0.286 , $p = 0.0242$ vs STD; HFD + PEA: 1.036 ± 0.202 ; $p > 0.9999$ vs STD; $p = 0.0303$ vs HFD) and CRHR1 (Fig. 4D, F (2, 12) = 1.415; STD: 1.000 ± 0.106 ; HFD: 1.800 ± 0.234 , $p = 0.0110$ vs STD; HFD + PEA: 0.822 ± 0.089 ; $p > 0.9999$ vs STD; $p = 0.0026$ vs HFD) in obese mice. By peroxidase immunohistochemistry, we evaluated the number of Iba1-positive microglial cells (Fig. 4E) and the immunoreactive area (%) of GFAP-positive astrocytes (Fig. 4F) in the arcuate nucleus, taken as indices of HFD-induced hypothalamic inflammation. As expected (Buckman et al., 2013; Valdearcos et al., 2014), HFD produced a significant microgliosis and astrogliosis in the hypothalamic arcuate nucleus, that were counteracted by PEA treatment (Fig. 4E, F (2, 12) = 0.2209; STD: 119.6 ± 4.534 ; HFD: 162.6 ± 3.669 , $p < 0.0001$ vs STD; HFD + PEA: 136.2 ± 5.286 ; $p = 0.0719$ vs STD; $p = 0.0044$ vs HFD; Fig. 4F, F (2, 12) = 0.0323; STD: 19.43 ± 1.280 ; HFD: 24.71 ± 1.257 , $p = 0.0325$ vs STD; HFD + PEA: 18.18 ± 1.185 ; $p > 0.9999$ vs STD; $p = 0.0087$ vs HFD).

3.4. PEA limits hippocampal inflammation, astrogliosis, and microgliosis of obese mice.

Since the alteration of bidirectional network between hypothalamus and hippocampus represents the pathogenetic basis for neuropsychiatric disorders related to obesity (Miller and Spencer, 2014), we also evaluated inflammation, astrogliosis and microgliosis in hippocampus of all animal groups. PEA reduced mRNA expression of TNF- α (Fig. 5A, F (2, 12) = 6.133; STD: 1.000 ± 0.110 ; HFD: 4.307 ± 0.858 , $p = 0.0017$ vs STD; HFD + PEA: 0.603 ± 0.118 ; $p > 0.9999$ vs STD; $p = 0.0007$ vs HFD) and IL-1 β (Fig. 5B, F (2, 12) = 4.923; STD: 1.000 ± 0.970 ; HFD: 4.173 ± 0.921 , $p = 0.0043$ vs STD; HFD + PEA: 1.505 ± 0.177 ; $p > 0.9999$ vs STD; $p = 0.0140$ vs HFD), altered by HFD. Then, we analyzed the distribution of Iba1-positive cells and the percentage of GFAP specific staining in the DG and in the stratum radiatum of the CA1 hippocampus (Fig. 5C and F). HFD caused a marked microgliosis, as shown by the significant increase of the number of Iba1-positive cells in both DG and stratum radiatum. Interestingly, PEA attenuated this detrimental condition in a significant manner in the stratum radiatum, and only partially in the DG (Fig. 5D, F (2, 12) = 0.1838; STD: 97.60 ± 7.109 ; HFD: 123.2 ± 4.283 , $p = 0.0280$ vs STD; HFD + PEA: 113.9 ± 5.828 ; $p = 0.2161$ vs STD; $p = 0.8547$ vs HFD; Fig. 5G, F (2, 12) = 0.0087; STD: 76.47 ± 2.284 ; HFD: 90.27 ± 1.971 , $p = 0.0017$ vs STD; HFD + PEA: 79.67 ± 2.035 ; 0.9082 vs STD; $p = 0.0116$ vs HFD). Accordingly, HFD strongly induced an increase of GFAP-positive immunoreactive area (%) in DG, that was reverted by PEA (Fig. 5E, F (2, 12) = 2.342; STD: 7.980 ± 0.101 ; HFD: 10.64 ± 0.473 , $p = 0.0015$ vs STD; HFD + PEA: 8.030 ± 0.496 ; $p > 0.9999$ vs STD; $p = 0.0018$ vs HFD). HFD involved a tendency to an increase of GFAP-positive immunoreactive area (%) in stratum




Fig. 4. PEA counteracts hypothalamic injury in HFD-induced obese mice. The mRNA transcription of (A) *Nfkb1*, (B) *Il1b*, (C) *Crh*, and (D) *Crhr1* in the hypothalamus (n = 5 per group). Immunohistochemical evaluations and morphometric analyses of (E) the number of IBA1-positive microglial cells and (F) GFAP immunoreactive area in the hypothalamic arcuate nucleus (Arc) (n = 5 per group). 3 V, third ventricle, ME, median eminence. All data are shown as mean \pm S.E.M. * $p < 0.05$, ** $p < 0.01$, and **** $p < 0.0001$.

radiatum, that was partially reduced by PEA (Fig. 5H, F (2, 12) = 1.035; STD: 6.608 ± 0.477 ; HFD: 7.150 ± 0.592 , $p > 0.9999$ vs STD; HFD + PEA: 5.684 ± 0.269 ; $p = 0.5582$ vs STD; $p = 0.1380$ vs HFD).

3.5. PEA effects on neuroinflammation, mast cell proteases, and BBB permeability in the hippocampus of obese mice.

The peripheral endotoxemia caused by HFD intake also reflected in hippocampus, where the lipid overload caused an increase of protein TLR4 (Fig. 6A, F (2, 13) = 0.5691; STD: 0.596 ± 0.112 ; HFD: 1.173 ± 0.067 , $p = 0.0019$ vs STD; HFD + PEA: 0.698 ± 0.082 , $p > 0.9999$ vs STD; $p = 0.0060$ vs HFD), its downstream gene *Myd88* (Fig. 6B, F (2, 12) = 2.811; STD: 1.000 ± 0.045 ; HFD: 1.552 ± 0.133 , $p = 0.0013$ vs STD; HFD + PEA: 0.851 ± 0.018 ; $p = 0.6627$ vs STD; $p = 0.0002$ vs HFD), and the transcription of TLR2 (Fig. 6C, F (2, 12) = 0.1345; STD: 1.000 ± 0.009 ; HFD: 1.151 ± 0.012 , $p < 0.0001$ vs STD; HFD + PEA: 0.812 ± 0.014 ; $p < 0.0001$ vs STD; $p < 0.0001$ vs HFD), all immune factors reduced by PEA treatment. Furthermore, PEA reduced mRNA expression of two specific proteases of murine mast cells, *Cma1* (Fig. 6D, F (2, 12) = 2.925; STD: 1.000 ± 0.232 ; HFD: 2.037 ± 0.391 , $p = 0.0498$ vs STD; HFD + PEA: 0.408 ± 0.042 ; $p = 0.4148$ vs STD; $p = 0.0027$ vs HFD) and *Tpsb2* (Fig. 6E, F (2, 12) = 1.641; STD: 1.000 ± 0.252 ; HFD: 2.031 ± 0.245 , $p = 0.0127$ vs STD; HFD + PEA: 0.748 ± 0.073 ; $p > 0.9999$ vs STD; $p = 0.0027$ vs HFD), increased by HFD. The detrimental process of neuroinflammation triggered by HFD caused the loss of BBB integrity, as shown by the reduced transcription of *Tjp1* (Fig. 6F, F (2, 12) = 0.2657; STD: 1.000 ± 0.048 ; HFD: 0.733 ± 0.037 , $p = 0.0042$ vs STD; HFD + PEA: 0.963 ± 0.051 ; $p > 0.9999$ vs STD; $p = 0.0116$ vs HFD), *Ocln* (Fig. 6G, F (2, 12) = 1.091; STD: 1.000 ± 0.059 ; HFD: 0.724 ± 0.020 , $p = 0.0042$ vs STD; HFD + PEA: 1.030 ± 0.053 ; $p > 0.9999$ vs STD; $p = 0.0019$ vs HFD), and *Cldn5* (Fig. 6H, F (2, 12) = 0.9122; STD: 1.000 ± 0.029 ; HFD: 0.731 ± 0.060 , $p = 0.0037$ vs STD; HFD + PEA: 0.964 ± 0.042 ; $p > 0.9999$ vs STD; $p = 0.0103$ vs HFD), whose levels were improved by PEA. To provide further evidence of PEA-mediated effect on BBB integrity, we resorted to immunoreactivity against endogenous

albumin which extravasates following disruption of the BBB (Saunders et al., 2015; Venema et al., 2020) and is taken up by neuronal and glial cells (Braganza et al., 2012; van Vliet et al., 2007). Results showed that HFD mice exhibited an increase in the number of scattered albumin-positive neurons in both DG (Fig. 6I, F (2, 12) = 0.1667; STD: 4.200 ± 0.3742 ; HFD: 7.000 ± 0.7746 , $p = 0.0261$ vs STD; HFD + PEA: 2.600 ± 0.6782 ; $p = 0.2967$ vs STD; $p = 0.0011$ vs HFD) and CA1 hippocampal subfield compared to STD mice (Fig. 6J, F (2, 12) = 2.211; STD: 4.200 ± 0.800 ; HFD: 6.600 ± 0.245 , $p = 0.0242$ vs STD; HFD + PEA: 3.400 ± 0.400 ; $p = 0.9346$ vs STD; $p = 0.0035$ vs HFD). PEA treatment reduced all these parameters.

3.6. The direct effect of PEA on neuroinflammation and mitochondrial dysfunction in *Gluc2*-insulted SH-SY5Y cells: PPAR- α involvement

An *in vitro* neuronal model of insulin resistance and metabolic inflammation was used for mechanistic studies (Mi et al., 2017). Human SH-SY5Y cells were challenged with a mix of glucose and glucosamine (Gluc2) to study the direct effect of PEA on neuroinflammation and mitochondrial dysfunction. Moreover, to evaluate the involvement of PPAR- α in PEA activity, the PPAR- α antagonist GW6471 was used (Fig. 7A). Cell treatment with PEA limited Gluc2-induced inflammation, reducing the transcription of TNF- α (Fig. 7B, F (3, 8) = 1.735; CON: 1.000 ± 0.004 ; Gluc2: 2.817 ± 0.186 $p < 0.0001$ vs CON; Gluc2 + PEA: 1.414 ± 0.078 , $p < 0.0001$ vs Gluc2; Gluc2 + GW + PEA: 2.262 ± 0.056 , $p = 0.0027$ vs Gluc2 + PEA), TLR4 (Fig. 7C, F (3, 8) = 0.5453; CON: 1.000 ± 0.016 ; Gluc2: 2.320 ± 0.186 , $p = 0.0043$ vs CON; Gluc2 + PEA: 0.580 ± 0.044 , $p = 0.0007$ vs Gluc2; Gluc2 + GW + PEA: 2.337 ± 0.294 , $p = 0.0006$ vs Gluc2 + PEA), and NLRP3 (Fig. 7D, F (3, 8) = 1.345; CON: 1.000 ± 0.003 ; Gluc2: 2.365 ± 0.185 , $p = 0.0002$ vs CON; Gluc2 + PEA: 1.501 ± 0.058 , $p = 0.0056$ vs Gluc2; Gluc2 + GW + PEA: 2.104 ± 0.141 , $p = 0.045$ vs Gluc2 + PEA). The anti-inflammatory activities of PEA were blunted by GW6471. In another set of experiments, we evaluated PEA effect on mitochondrial dysfunction of insulted SH-SY5Y cells, in presence or not of GW6471, using Mito Stress assay by Seahorse




Fig. 5. PEA limits neuroinflammation, astrogliosis and microgliosis in the hippocampus of HFD mice. The mRNA expression of (A) *Tnf* and (B) *Il1b* in the hippocampus of all experimental groups (n = 5 per group). The immunohistochemical analyses of Iba1-positive microglial cells and GFAP-positive astrocytes in (C) the DG and (F) stratum radiatum (n = 5 per group). The count of the number of positive cells for (D, G) Iba1 and (E, H) of GFAP immunoreactive in DG and stratum radiatum, respectively (n = 5 per group). Hil, hilus of the DG; Py, pyramidal cell layer; LMol, lacunosum molecular layer. All data are shown as mean ± S.E.M. *p < 0.05, **p < 0.01, and ***p < 0.001.




Fig. 6. The impact of PEA on immune activation, mast cell degranulation, and BBB integrity in the hippocampus of HFD mice. Western blot for (A) TLR4, and Real-Time PCR analysis of (B) *Myd88*, and (C) *Tlr2*, (D) *Cma1*, (E) *Tpsb2* (F) *Tjp1*, (G) *Ocln*, and (H) *Cldn5* in the hippocampus of all experimental groups (at least $n = 5$ per group for western blot; $n = 5$ per group for Real-Time PCR). Morphometric analysis of albumin-immunoreactive cells in hippocampal (I) DG and (J) CA1 subfield. As shown in the upper panels of I and J, most albumin-positive cells (green, arrowheads) are also positive for the neuronal marker NeuN (red, arrowheads). The lower panels of I and J represent images depicting albumin staining in the DG and, respectively, CA1 subfield for each experimental condition. Hil, hilus; Py, pyramidal cell layer. In the merged images, cell nuclei are stained with TO-PRO3. The semiquantitative evaluation of albumin-positive neuronal-like profiles ($n = 5$ per group) is also shown. All data are shown as mean \pm S.E.M. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.




Fig. 7. The role of PPAR-α in PEA effects on inflammation and mitochondrial function in glucose + glucosamine (Gluc2)-insulted SH-SY5Y cells. (A) The experimental protocol on human SH-SY5Y cells. The mRNA extracts of all treated cells for (B) TNF-α, (C) TLR4, and (D) NLRP3. (E) SH-SY5Y cells were undergone to Cell Mito Stress Test in Seahorse analyzer, evaluating the basal oxygen consumption rate (OCR), after the addition of oligomycin, the uncoupler FCCP, rotenone, and antimycin A. (F) Basal respiration, ATP production, proton leak, and maximal respiration were determined. OCR was normalized with the protein amount by Bradford assay. Data are the mean ± SEM of three different experiments with three replicates. All data are shown as mean ± S.E.M. **p* < 0.05, ***p* < 0.01, ****p* < 0.001, and *****p* < 0.0001.

analyzer (Fig. 7E). PEA treatment recovered mitochondrial energy metabolism altered by Gluc2 stimulation, improving basal and maximal respiration, promoting ATP production, and increasing proton leak (Fig. 7F). The co-incubation with GW6471 caused the loss of PEA effects, confirming the key role of PPAR- α (Basal respiration: F (3, 8) = 0.5116; CON: 87.43 ± 6.177 ; Gluc2: 48.03 ± 6.924 , $p = 0.0012$ vs CON; Gluc2 + PEA: 81.41 ± 3.223 , $p = 0.0047$ vs Gluc2; Gluc2 + GW + PEA: 50.35 ± 3.944 , $p = 0.081$ vs Gluc2 + PEA; ATP production: F (3, 8) = 0.5016; CON: 76.28 ± 5.694 ; Gluc2: 39.81 ± 6.119 , $p = 0.001$ vs CON; Gluc2 + PEA: 69.03 ± 2.816 , $p = 0.0059$ vs Gluc2; Gluc2 + GW + PEA: 40.65 ± 3.665 , $p = 0.0074$ vs Gluc2 + PEA; proton leak: F (3, 8) = 0.2326; CON: 11.14 ± 0.685 ; Gluc2: 8.213 ± 0.846 , $p = 0.0664$ vs CON; Gluc2 + PEA: 12.38 ± 0.465 , $p = 0.0065$ vs Gluc2; Gluc2 + GW + PEA: 9.7 ± 0.709 , $p = 0.1066$ vs Gluc2 + PEA; maximal respiration: F (3, 8) = 0.6235; CON: 116.8 ± 9.752 ; Gluc2: 48.20 ± 7.207 , $p < 0.0001$ vs CON; Gluc2 + PEA: 95.91 ± 4.976 , $p = 0.0021$ vs Gluc2; Gluc2 + GW + PEA: 75.84 ± 3.853 , $p = 0.359$ vs Gluc2 + PEA).

4. Discussion

Obesity is often associated with a high prevalence of mood disorders besides being a risk factor for other comorbidities, such as cardiovascular diseases, type 2 diabetes, and cancer (Farzi et al., 2019). Animal models of HFD feeding have already pinpointed how the inflammatory process associated with obesity may be involved in peripheral and brain disorders. Our recent data demonstrated the capability of PEA in limiting weight gain and hepatic metabolic dysfunction and inflammation, restoring glucose and lipid homeostasis in obese mice (Annunziata et al., 2020). PEA also showed beneficial effects on depressive-like phenotype and cognitive deficit in obese mice, related to virtuous pathways, which led to synaptic strength and neurogenesis (Lama et al., 2021).

Here, we show that HFD animals exhibited altered serum parameters, characterized by elevated levels of cytokines (TNF- α , IL-1 β), chemokines (MCP-1), and endotoxemia, defining meta-inflammation. Interestingly, PEA treatment counteracted the increase of circulating inflammatory factors, limiting the “knock-on effect” on peripheral or central tissues and related dysfunctions.

Fat overnutrition initially induces hypothalamic inflammation and dysfunction in response to excessive fatty acid flux (Cai and Khor, 2019; Lee et al., 2020). The hypothalamus also generates adaptive feedback signals to inflammation in other brain structures. Long-term HFD feeding induces hippocampal neuroinflammation (Wang et al., 2018) due to BBB leakage specifically in the hippocampus, rather than other brain structures, i.e., prefrontal cortex or cerebellum (Guillemot-Legris and Muccioli, 2017). In our study, PEA treatment not only limited inflammation in both hypothalamus (NF- κ B and IL-1 β) and hippocampus (TNF- α and IL-1 β) but also improved hippocampal BBB integrity restoring tight junction transcription and reducing endogenous albumin extravasation and neuronal uptake. The bolstering effect of PEA on BBB integrity was associated with a reduction of central immune cells, evidenced in both hypothalamus and hippocampus. Very recent findings pinpoint the protective effect of PEA in BBB dysfunction-related diseases. After cerebral ischaemic/reperfusion, PEA regulated paracellular permeability through the prevention of cytoskeletal alterations (Kong et al., 2021). Moreover, Li et al. (2021) showed that the inhibition of N-acylethanolamine acid amidase (NAAA), a specific deactivating PEA enzyme, significantly limited BBB disruption and alleviated the traumatic brain injury in mice, proposing a new therapeutic approach focused on NAAA/PEA/PPAR- α pathway.

Microglia and astrocytes play a pivotal role in obesity-induced neuroinflammation (Le Thuc et al., 2017; Yu et al., 2019). PEA showed its anti-inflammatory effects by the decreased GFAP and Iba1 positive cells in both areas compared to HFD-fed mice. Interestingly, glial cells are generally located close to mast cells in inflamed brain areas. Unlike resident microglia, mast cells reside in the brain parenchyma and can

cross BBB when impaired (Skaper, 2017). Since the perivascular location and the capability to release a broad range of pre-formed detrimental factors, mast cells play a role in the early phase of neuroinflammation, preceding glial activation (Wang et al., 2020). In our experimental conditions, besides glial marker decrease, PEA also reduced the transcription of murine specific chymase 1 and trypsin β 2 in the hippocampus, as a likely limited mast cell activation. These data suggest PEA capability to blunt the unwholesome interaction between mast cells and glia, whose activation strongly contributes to BBB leakage and neuroinflammation (Hendriksen et al., 2017).

Consistent with reducing hippocampal inflammation, PEA treatment down-regulated TLR2 and TLR4 with its downstream coactivator MyD88. In obesity-induced neuroinflammation TLR4 was found over-expressed in hypothalamus and hippocampus (Guillemot-Legris and Muccioli, 2017), where TLR4 pathway can be activated by saturated fatty acids similarly to LPS (Rocha et al., 2016). The activation of TLR4/MyD88 pathway triggers the release of cytokines and chemokines which induces innate immune response and the following neuroinflammation (Leitner et al., 2019). Therefore, the reduced expression of TLR4 by PEA is consistent with the shutdown of the inflammatory cascade. Notably, TLR4 and TLR2 activation on mast cells increases cytokine release, favouring microglial pro-inflammatory response, which in turn amplifies mast cell-induced TLR overexpression (Pietrzak et al., 2011). As our data demonstrated, the blunted synthesis of pro-inflammatory cytokines by PEA can stop this vicious cycle among brain immune cells, limiting the progression of enduring neuroinflammation. On the other hand, PEA showed a neuroprotective effect on the hippocampus by improving neurogenesis and synaptic plasticity (Cristiano et al., 2018; Lama et al., 2021).

Lines of evidence showed that obesity is associated with HPA axis dysregulation (Dionysopoulou et al., 2021), which contributes to the pathogenesis of anxiety (Tafet and Nemeroff, 2020). Neuroinflammation affects hypothalamic inter-connections with brain regions regulating mood and anxiety and increases CRH release (Silverman et al., 2005). Consistently, our data demonstrated an increased transcription of CRH and its receptor CRHR1 in the hypothalamus of obese mice, normalized by PEA treatment. Nevertheless, in our experimental conditions, no change in serum ACTH and corticosterone levels was shown among groups, according to previous data on HFD-fed mice (Lizarbe et al., 2018; Pierre et al., 2019). These findings suggest an impairment of the HPA system, mostly implicating the hypothalamus.

Several preclinical studies have already demonstrated the anxiolytic effect of PEA, such as chronic corticosterone exposure (Crupi et al., 2013) or the socially isolated mouse exposed to fear conditioning (Locci and Pinna, 2019) without any metabolic dysfunction. Here, we demonstrate the counteractive effect of PEA on anxiety-like behavior induced by HFD in mice. In open field test, PEA-treated mice were more prone to explore “dangerous” areas and likely exposed to potential threats than untreated obese mice.

Since the amygdalar complex is considered an important site in managing the stress response and anxiety-related behaviors (Roozendaal et al., 2009), we evaluated neurochemical monoamine and neurotransmitter patterns in this brain area. The behavioral improvement induced by PEA was paralleled by a non-significant trend of reduction of noradrenaline and 5-HT. Conversely, PEA-induced decrease in DA levels, without significant change in DOPAC and HVA, leads to an increase in DA turnover, thus suggesting the involvement of different pathways other than catabolic enzymes. Evidence on the mechanisms underlying mood disorders has shown an impairment of the excitatory-inhibitory balance involving glutamatergic and GABAergic neurotransmission in the amygdala. Notably, GLU levels were unchanged under overnutrition, while the reduction of GABA levels was reverted by PEA treatment, indicating a restoration of GABAergic inhibitory control. This finding is consistent with PEA capability in inducing an increase in allopregnanolone levels (Locci and Pinna, 2019; Sasso et al., 2012), leading to a reinforcement of GABAergic tone through the positive

modulation of GABA(A) receptor by the hormone.

Our data show a relevant effect of PEA on the meta-inflammation in obese mice, reducing systemic detrimental factors which impair the BBB and trigger neuroinflammation. However, we cannot exclude a direct central effect of PEA since it can cross the BBB after peripheral administration (Petrosino and Di Marzo, 2017), even more in the ultramicro-nized formulation with improved oral bioavailability and efficacy (Petrosino et al., 2018). As previously shown by pharmacokinetics studies, 20 min after oral administration, PEA is mainly accumulated in the rat hypothalamus (Artamonov et al., 2005). Similarly, Beggiato et al. (2020) showed more recently that orally administered ultramicro-nized PEA is adsorbed and distributed in the mouse hypothalamus, measuring a significant peak of plasmatic and tissue concentrations between 1.0- and 1.5-hour post-administration and a drop to baseline values after 4 h. Consistently, we found similar concentrations of PEA 4 h-post administration in the hypothalamus of treated and untreated HFD mice, and a similar pattern of concentrations was shown in the hippocampus. However, while no relevant difference was shown in hippocampal levels among groups, a significant increase of PEA levels was revealed in the hypothalamus from PEA-treated HFD animals than STD mice (Figure S2).

The possible direct central effect is supported by *in vitro* experiments on neuronal cells. We have demonstrated PEA capability in reducing the expression of different inflammatory markers (i.e., TNF- α , TLR4, and NLRP3) associated with the metabolic challenge of glucose and glucosamine. In addition, PEA significantly restored mitochondrial bioenergetics in terms of basal and maximal respiration, ATP-linked respiration, and proton leak. Indeed, mitochondrial dysfunction has been closely associated with stress-related central disorders, leading to altered brain metabolism, synaptic function, and plasticity (Daniels et al., 2020; Reddy and Beal, 2008). We have recently demonstrated that HFD consumption led to mitochondrial dysfunction in the brain synaptosomal fraction. This alteration paralleled with the reduction of brain-derived neurotrophic factor (Cavaliere et al., 2019), a key brain signaling molecule stimulated by PEA treatment in different animal models (Lama et al., 2021; Cristiano et al., 2018). Notably, in *in vitro* experiments, we showed the involvement of PPAR- α activation in the PEA effects since the blockade of the receptor by the selective antagonist GW6471 blunted PEA anti-inflammatory activity and reversed the improvement of mitochondrial bioenergetics. Other findings have demonstrated the direct PPAR- α -mediated effects of PEA at central level. Locci and Pinna (2019) revealed that PEA induced corticolimbic allo-pregnanolone synthesis in an animal model of post-traumatic stress disorder, evidencing the obligatory role of PPAR- α in PEA effects. These findings were consistent with our previous data on the *de novo* synthesis of neurosteroids by PEA in astrocytes and the modulation of pentobarbital-evoked hypnotic effect in mice (Mattace Raso et al., 2011; Sasso et al., 2010). Although our study showed for the first time PEA effect on HFD-induced anxiety-like behavior, there are some limitations. It would be interesting to discriminate between central and peripheral mechanisms, that are strictly interconnected in this model, and to address the different impact of their contribution in the neuroprotective and anti-inflammatory effect of PEA. However, the pharmacological control of inflammation, immunity, and neurotransmitter imbalance by PEA strengthens its therapeutic potential for neuropsychiatric comorbidities of obesity, also considering its pleiotropic properties, safety profile, and converging homeostatic mechanisms affecting central targets.

Funding

This work was partially supported by a grant assigned to Prof. Rosaria Meli from Epitech Group S.p.A. Dr. Adriano Lama acknowledges that he has benefited from a fellowship sponsored by Epitech Group S.p.A. Prof. Sabrina Diano was supported by the NIH DK120321 and DK097566. Dr. Stefania Petrosino is an employee of Epitech Group SpA

and is co-inventor on patent on Adelmidrol, which is unrelated to the present study.

Acknowledgments

This article is dedicated to the memory of dr. Francesco Della Valle, who passed away while this paper was being peer-reviewed. Those who have known him, miss his devotion to science and life. We thank Mr. Giovanni Esposito, Mr. Angelo Russo, and Dr. Antonio Baiano for animal care and technical assistance. Giuseppina Mattace Raso and Rosaria Meli were recipients of the “Programme of International Exchange (2017) between the University of Naples Federico II and Foreign Universities or Research centres for short-term mobility” to collaborate with Sabrina Diano (Yale University, New Haven). Adriano Lama received a 1-year outgoing international fellowship issued by the Italian Society of Pharmacology (2017) to join Sabrina Diano’s lab. Italian Ministry of Economic Development (MISE) partially financed the study (Project n. F/200052/01/X45).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bbi.2022.02.008>.

References

- Annunziata, C., Lama, A., Pirozzi, C., Cavaliere, G., Trinchese, G., Di Guida, F., Nitro Izzo, A., Cimmino, F., Paciello, O., De Biase, D., Murrù, E., Banni, S., Calignano, A., Mollica, M.P., Mattace Raso, G., Meli, R., 2020. Palmitoylethanolamide counteracts hepatic metabolic inflexibility modulating mitochondrial function and efficiency in diet-induced obese mice. *FASEB J.* 34 (1), 350–364. <https://doi.org/10.1096/fj.201901510RR>.
- Araujo, J.R., Tomas, J., Brenner, C., Sansonetti, P.J., 2017. Impact of high-fat diet on the intestinal microbiota and small intestinal physiology before and after the onset of obesity. *Biochimie* 141, 97–106. <https://doi.org/10.1016/j.biochi.2017.05.019>.
- Artamonov, M., Zhukov, O., Shuba, I., Storozhuk, L., Khmel, T., Klimashevsky, V., Mikosha, A., Gula, N., 2005. Incorporation of labelled N-acyl ethanolamine (NAE) into rat brain regions *in vivo* and adaptive properties of saturated NAE under x-ray irradiation. *Ukr. Biokhim. Zh.* 1999 (77), 51–62.
- Baker, K.D., Loughman, A., Spencer, S.J., Reichelt, A.C., 2017. The impact of obesity and hypercaloric diet consumption on anxiety and emotional behavior across the lifespan. *Neurosci. Biobehav. Rev.* 83, 173–182. <https://doi.org/10.1016/j.neubiorev.2017.10.014>.
- Beggiato, Sarah, Tomasini, Maria Cristina, Cassano, Tommaso, Ferraro, Luca, 2020. Chronic oral palmitoylethanolamide administration rescues cognitive deficit and reduces neuroinflammation, oxidative stress, and glutamate levels in a transgenic murine model of Alzheimer’s Disease. *Journal of Clinical Medicine* 9(2), 428. <https://doi.org/10.3390/jcm9020428>.
- Berkseth, K.E., Guyenet, S.J., Melhorn, S.J., Lee, D., Thaler, J.P., Schur, E.A., Schwartz, M.W., 2014. Hypothalamic gliosis associated with high-fat diet feeding is reversible in mice: a combined immunohistochemical and magnetic resonance imaging study. *Endocrinology* 155, 2858–2867. <https://doi.org/10.1210/en.2014-1121>.
- Braganza, O., Bedner, P., Huttman, K., von Staden, E., Friedman, A., Seifert, G., Steinhauser, C., 2012. Albumin is taken up by hippocampal NG2 cells and astrocytes and decreases gap junction coupling. *Epilepsia* 53, 1898–1906. <https://doi.org/10.1111/j.1528-1167.2012.03665.x>.
- Buckman, L.B., Thompson, M.M., Moreno, H.N., Ellacott, K.L.J., 2013. Regional astroglial gliosis in the mouse hypothalamus in response to obesity. *J. Comp. Neurol.* 521 (6), 1322–1333. <https://doi.org/10.1002/cne.23233>.
- Cai, D., Khor, S., 2019. “Hypothalamic Microinflammation” paradigm in aging and metabolic diseases. *Cell Metab.* 30 (1), 19–35. <https://doi.org/10.1016/j.cmet.2019.05.021>.
- Cavaliere, G., Trinchese, G., Penna, E., Cimmino, F., Pirozzi, C., Lama, A., Annunziata, C., Catapano, A., Mattace Raso, G., Meli, R., Monda, M., Messina, G., Zammit, C., Crispino, M., Mollica, M.P., 2019. High-fat diet induces neuroinflammation and mitochondrial impairment in mice cerebral cortex and synaptic fraction. *Front. Cell. Neurosci.* 13, 509. <https://doi.org/10.3389/fncel.2019.00509>.
- Cristiano, C., Pirozzi, C., Coretti, L., Cavaliere, G., Lama, A., Russo, R., Lembo, F., Mollica, M.P., Meli, R., Calignano, A., Mattace Raso, G., 2018. Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: contribution of central and peripheral mechanisms. *Brain Behav. Immun.* 74, 166–175. <https://doi.org/10.1016/j.bbi.2018.09.003>.
- Crupi, R., Paterniti, I., Ahmad, A., Campolo, M., Esposito, E., Cuzzocrea, S., 2013. Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. *CNS Neurol. Disord. Drug Targets* 12, 989–1001. <https://doi.org/10.2174/18715273113129990084>.

- Daniels, T.E., Olsen, E.M., Tyrka, A.R., 2020. Stress and Psychiatric Disorders: The Role of Mitochondria. *Annu. Rev. Clin. Psychol.* 16 (1), 165–186. <https://doi.org/10.1146/annurev-clinpsy-082719-104030>.
- Dionysopoulou, S., Charmandari, E., Bargiota, A., Vlahos, N.F., Mastorakos, G., Valsamakis, G., 2021. The role of hypothalamic inflammation in diet-induced obesity and its association with cognitive and mood disorders. *Nutrients* 13 (2), 498. <https://doi.org/10.3390/nu13020498>.
- Douglass, J.D., Dorfman, M.D., Fasnacht, R., Shaffer, L.D., Thaler, J.P., 2017. Astrocyte IKKbeta/NF-kappaB signaling is required for diet-induced obesity and hypothalamic inflammation. *Mol. Metab.* 6, 366–373. <https://doi.org/10.1016/j.molmet.2017.01.010>.
- Farzi, A., Hassan, A.M., Zenz, G., Holzer, P., 2019. Diabesity and mood disorders: Multiple links through the microbiota-gut-brain axis. *Mol. Aspects Med.* 66, 80–93. <https://doi.org/10.1016/j.mam.2018.11.003>.
- Guillemot-Legrès, O., Muccioli, G.G., 2017. Obesity-induced neuroinflammation: beyond the hypothalamus. *Trends Neurosci.* 40 (4), 237–253. <https://doi.org/10.1016/j.tins.2017.02.005>.
- Hendriksen, E., van Bergeijk, D., Oosting, R.S., Redegeld, F.A., 2017. Mast cells in neuroinflammation and brain disorders. *Neurosci. Biobehav. Rev.* 79, 119–133. <https://doi.org/10.1016/j.neubiorev.2017.05.001>.
- Kong, D., Xie, B., Li, Y., Xu, Y., 2021. PEA prevented early BBB disruption after cerebral ischaemic/reperfusion (I/R) injury through regulation of ROCK/MLC signaling. *Biochem. Biophys. Res. Commun.* 566, 164–169. <https://doi.org/10.1016/j.bbrc.2021.06.019>.
- Lama, A., Annunziata, C., Coretti, L., Pirozzi, C., Di Guida, F., Nitrito Izzo, A., Cristiano, C., Mollica, M.P., Chiariotti, L., Pelagalli, A., Lembo, F., Meli, R., Mattace Raso, G., 2019. N-(1-carbamoyl-2-phenylethyl) butyramide reduces antibiotic-induced intestinal injury, innate immune activation and modulates microbiota composition. *Sci. Rep.* 9, 4832. <https://doi.org/10.1038/s41598-019-41295-x>.
- Lama, A., Pirozzi, C., Annunziata, C., Morgese, M.G., Senzacqua, M., Severi, I., Calignano, A., Trabace, L., Giordano, A., Meli, R., Mattace Raso, G., 2021. Palmitoylethanolamide counteracts brain fog improving depressive-like behaviour in obese mice: possible role of synaptic plasticity and neurogenesis. *Br. J. Pharmacol.* 178 (4), 845–859. <https://doi.org/10.1111/bph.15071>.
- Le Thuc, O., Stobbe, K., Cansell, C., Nahon, J.L., Blondeau, N., Rovere, C., 2017. Hypothalamic inflammation and energy balance disruptions: spotlight on chemokines. *Front. Endocrinol. (Lusanna)* 8, 197. <https://doi.org/10.3389/fendo.2017.00197>.
- Lee, C.H., Suk, K., Yu, R., Kim, M.S., 2020. Cellular contributors to hypothalamic inflammation in obesity. *Mol. Cells* 43, 431–437. <https://doi.org/10.14348/molcells.2020.0055>.
- Leitner, G.R., Wenzel, T.J., Marshall, N., Gates, E.J., Klegeris, A., 2019. Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders. *Expert Opin. Ther. Targets* 23 (10), 865–882. <https://doi.org/10.1080/14728222.2019.1676416>.
- Li, C., Xu, M.M., Wang, K., Adler, A.J., Vella, A.T., Zhou, B., 2018. Macrophage polarization and meta-inflammation. *Transl. Res.* 191, 29–44. <https://doi.org/10.1016/j.trsl.2017.10.004>.
- Li, Y., Zhou, P., Hu, T., Ren, J., Xu, Y., Qiu, Y., Lu, C., Li, Y., 2021. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI). *Eur. J. Pharmacol.* 912, 174561. <https://doi.org/10.1016/j.ejphar.2021.174561>.
- Lizarbe, B., Soares, A.F., Larsson, S., Duarte, J.M.N., 2018. Neurochemical modifications in the hippocampus, cortex and hypothalamus of mice exposed to long-term high-fat diet. *Front. Neurosci.* 12, 985. <https://doi.org/10.3389/fnins.2018.00985>.
- Locci, A., Pinna, G., 2019. Stimulation of peroxisome proliferator-activated receptor-alpha by N-palmitoylethanolamine engages allopregnanolone biosynthesis to modulate emotional behavior. *Biol. Psychiatry* 85, 1036–1045. <https://doi.org/10.1016/j.biopsych.2019.02.006>.
- Mattace Raso, G., Esposito, E., Vitiello, S., Iacono, A., Santoro, A., D'Agostino, G., Sasso, O., Russo, R., Piazza, P.V., Calignano, A., Meli, R., 2011. Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-alpha. *J. Neuroendocrinol.* 23, 591–600. <https://doi.org/10.1111/j.1365-2826.2011.02152.x>.
- Mattace Raso, G., Russo, R., Calignano, A., Meli, R., 2014a. Palmitoylethanolamide in CNS health and disease. *Pharmacol. Res.* 86, 32–41. <https://doi.org/10.1016/j.phrs.2014.05.006>.
- Mattace Raso, G., Santoro, A., Russo, R., Simeoli, R., Paciello, O., Di Carlo, C., Diano, S., Calignano, A., Meli, R., 2014b. Palmitoylethanolamide prevents metabolic alterations and restores leptin sensitivity in ovariectomized rats. *Endocrinology* 155, 1291–1301. <https://doi.org/10.1210/en.2013-1823>.
- Mi, Y., Qi, G., Fan, R., Qiao, Q., Sun, Y., Gao, Y., Liu, X., 2017. EGCG ameliorates high-fat- and high-fructose-induced cognitive defects by regulating the IRS/AKT and ERK/CREB/BDNF signaling pathways in the CNS. *FASEB J.* 31 (11), 4998–5011. <https://doi.org/10.1096/fj.20170400RR>.
- Milaneschi, Y., Simmons, W.K., van Rossum, E.F.C., Penninx, B.W., 2019. Depression and obesity: evidence of shared biological mechanisms. *Mol. Psychiatry* 24 (1), 18–33. <https://doi.org/10.1038/s41380-018-0017-5>.
- Miller, A.A., Spencer, S.J., 2014. Obesity and neuroinflammation: a pathway to cognitive impairment. *Brain Behav. Immun.* 42, 10–21. <https://doi.org/10.1016/j.bbi.2014.04.001>.
- Petrosino, S., Cordaro, M., Verde, R., Schiano Moriello, A., Marcolongo, G., Schievano, C., Siracusa, R., Piscitelli, F., Peritore, A.F., Crupi, R., Impellizzeri, D., Esposito, E., Cuzzocrea, S., Di Marzo, V., 2018. Oral ultramicrosized palmitoylethanolamide: plasma and tissue levels and spinal anti-hyperalgesic effect. *Front. Pharmacol.* 9, 249. <https://doi.org/10.3389/fphar.2018.00249>.
- Petrosino, S., Di Marzo, V., 2017. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. *Br. J. Pharmacol.* 174 (11), 1349–1365. <https://doi.org/10.1111/bph.13580>.
- Pierre, A., Regin, Y., Van Schuerbeek, A., Fritz, E.M., Muylle, K., Beckers, T., Smolders, I. J., Singewald, N., De Bundel, D., 2019. Effects of disrupted ghrelin receptor function on fear processing, anxiety and saccharin preference in mice. *Psychoneuroendocrinology* 110, 104430. <https://doi.org/10.1016/j.psyneuen.2019.104430>.
- Pietrzak, A., Wierzbicki, M., Wiktorska, M., Brzezińska-Błaszczak, E., 2011. Surface TLR2 and TLR4 expression on mature rat mast cells can be affected by some bacterial components and proinflammatory cytokines. *Mediators Inflamm.* 2011, 1–11. <https://doi.org/10.1155/2011/427473>.
- Pirozzi, C., Lama, A., Annunziata, C., Cavaliere, G., De Caro, C., Citraro, R., Russo, E., Tallarico, M., Iannone, M., Ferrante, M.C., Mollica, M.P., Mattace Raso, G., De Sarro, G., Calignano, A., Meli, R., 2020. Butyrate prevents valproate-induced liver injury: In vitro and in vivo evidence. *FASEB J.* 34 (1), 676–690. <https://doi.org/10.1096/fj.201909027RR>.
- Reddy, P.H., Beal, M.F., 2008. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. *Trends Mol. Med.* 14 (2), 45–53. <https://doi.org/10.1016/j.molmed.2007.12.002>.
- Rocha, D.M., Caldas, A.P., Oliveira, L.L., Bressan, J., Hermsdorff, H.H., 2016. Saturated fatty acids trigger TLR4-mediated inflammatory response. *Atherosclerosis* 244, 211–215.
- Roosendaal, B., McEwen, B.S., Chattarji, S., 2009. Stress, memory and the amygdala. *Nat. Rev. Neurosci.* 10 (6), 423–433. <https://doi.org/10.1038/nrn2651>.
- Sasso, O., La Rana, G., Vitiello, S., Russo, R., D'Agostino, G., Iacono, A., Russo, E., Citraro, R., Cuzzocrea, S., Piazza, P.V., De Sarro, G., Meli, R., Calignano, A., 2010. Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice: involvement of allopregnanolone biosynthesis. *Eur. Neuropsychopharmacol.* 20 (3), 195–206. <https://doi.org/10.1016/j.euroneuro.2009.09.003>.
- Sasso, O., Russo, R., Vitiello, S., Raso, G.M., D'Agostino, G., Iacono, A., La Rana, G., Vallee, M., Cuzzocrea, S., Piazza, P.V., Meli, R., Calignano, A., 2012. Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain. *Pain* 153, 33–41. <https://doi.org/10.1016/j.pain.2011.08.010>.
- Saunders, N.R., Dziegielewska, K.M., Møllgaard, K., Habgood, M.D., 2015. Markers for blood-brain barrier integrity: how appropriate is Evans blue in the twenty-first century and what are the alternatives? *Front. Neurosci.* 9, 385. <https://doi.org/10.3389/fnins.2015.00385>.
- Seibenhener, M.L., Wooten, M.C., 2015. Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. *J. Vis. Exp.* e52434 <https://doi.org/10.3791/52434>.
- Silverman, M.N., Pearce, B.D., Biron, C.A., Miller, A.H., 2005. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. *Viral Immunol.* 18 (1), 41–78. <https://doi.org/10.1089/vim.2005.18.41>.
- Skaper, S.D., 2017. Impact of inflammation on the blood-neural barrier and blood-nerve interface: from review to therapeutic preview. *Int. Rev. Neurobiol.* 137, 29–45. <https://doi.org/10.1016/bs.irn.2017.08.004>.
- Skaper, S.D., Facci, L., Zusso, M., Giusti, P., 2017. Neuroinflammation, mast cells, and glia: dangerous liaisons. *Neuroscientist* 23 (5), 478–498. <https://doi.org/10.1177/10738584166687249>.
- Tafet, G.E., Nemeroff, C.B., 2020. Pharmacological treatment of anxiety disorders: the role of the HPA Axis. *Front. Psychiatry* 11, 443. <https://doi.org/10.3389/fpsy.2020.00443>.
- Tsan, L., Decarie-Spain, L., Noble, E.E., Kanoski, S.E., 2021. Western diet consumption during development: setting the stage for neurocognitive dysfunction. *Front. Neurosci.* 15, 632312. <https://doi.org/10.3389/fnins.2021.632312>.
- Valdearcos, M., Robblee, M., Benjamin, D., Nomura, D., Xu, A., Koliwad, S., 2014. Microglia dictate the impact of saturated fat consumption on hypothalamic inflammation and neuronal function. *Cell Rep.* 9 (6), 2124–2138. <https://doi.org/10.1016/j.celrep.2014.11.018>.
- Valdearcos, M., Douglass, J.D., Robblee, M.M., Dorfman, M.D., Stifler, D.R., Bennett, M. L., Gerritse, I., Fasnacht, R., Barres, B.A., Thaler, J.P., Koliwad, S.K., 2017. Microglial inflammatory signaling orchestrates the hypothalamic immune response to dietary excess and mediates obesity susceptibility. *Cell Metab.* 26 (1), 185–197.e3. <https://doi.org/10.1016/j.cmet.2017.05.015>.
- van Vliet, E.A., da Costa Araujo, S., Redeker, S., van Schaik, R., Aronica, E., Gorter, J.A., 2007. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. *Brain* 130 (2), 521–534. <https://doi.org/10.1093/brain/awl318>.
- Venema, W., Severi, I., Perugini, J., Di Mercurio, E., Mainardi, M., Maffei, M., Cinti, S., Giordano, A., 2020. Ciliary neurotrophic factor acts on distinctive hypothalamic arcuate neurons and promotes leptin entry into and action on the mouse hypothalamus. *Front. Cell. Neurosci.* 14, 140. <https://doi.org/10.3389/fncel.2020.00140>.
- Waise, T.M.Z., Toshinai, K., Naznin, F., NamKoong, C., Md Moin, A.S., Sakoda, H., Nakazato, M., 2015. One-day high-fat diet induces inflammation in the nodose ganglion and hypothalamus of mice. *Biochem. Biophys. Res. Commun.* 464 (4), 1157–1162. <https://doi.org/10.1016/j.bbrc.2015.07.097>.

- Wang, Y., Sha, H., Zhou, L., Chen, Y., Zhou, Q., Dong, H., Qian, Y., 2020. The mast cell is an early activator of lipopolysaccharide-induced neuroinflammation and blood-brain barrier dysfunction in the hippocampus. *Mediators Inflamm.* 2020, 1–15.
- Wang, Q., Yuan, J., Yu, Z., Lin, L.i., Jiang, Y., Cao, Z., Zhuang, P., Whalen, M.J., Song, B. o., Wang, X.-J., Li, X., Lo, E.H., Xu, Y., Wang, X., 2018. FGF21 attenuates high-fat diet-induced cognitive impairment via metabolic regulation and anti-inflammation of obese mice. *Mol. Neurobiol.* 55 (6), 4702–4717. <https://doi.org/10.1007/s12035-017-0663-7>.
- Yu, M., Huang, H., Dong, S., Sha, H., Wei, W., Liu, C., 2019. High mobility group box-1 mediates hippocampal inflammation and contributes to cognitive deficits in high-fat high-fructose diet-induced obese rats. *Brain Behav. Immun.* 82, 167–177. <https://doi.org/10.1016/j.bbi.2019.08.007>.